| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/01/2010 | US20100168086 7,8,10,10a-tetrahydro-6h-benzo[c]chromen-9(6ah)-one modulators of cannabinoid receptors |
| 07/01/2010 | US20100168081 Galantamine as a neuroprotective drug for retinal ganglion cells |
| 07/01/2010 | US20100168079 Biaryl Benzylamine Derivatives |
| 07/01/2010 | US20100168078 S1p receptor modulators for treating multiple sclerosis |
| 07/01/2010 | US20100168077 Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof |
| 07/01/2010 | US20100168075 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions |
| 07/01/2010 | US20100168070 Compounds for the treatment of alzheimer's disease |
| 07/01/2010 | US20100168068 Mao-b inhibitors useful for treating obesity |
| 07/01/2010 | US20100168053 Oral delivery system for methylcobalamin to treat disorders |
| 07/01/2010 | US20100168051 Altered Mitochondrial Activity in Diseases Resulting From Oxidative Stress |
| 07/01/2010 | US20100168039 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions |
| 07/01/2010 | US20100168032 Smart Pro-Drugs of Serine Protease Inhibitors |
| 07/01/2010 | US20100168023 Injectable Botulinum Toxin Formulations |
| 07/01/2010 | US20100168021 Urocortin proteins and uses thereof |
| 07/01/2010 | US20100168016 Diagnosis and treatment of diseases caused by misfolded proteins |
| 07/01/2010 | US20100168013 Neuromedin and FN-38 Peptides for Treating Psychiatric Diseases |
| 07/01/2010 | US20100168003 Agent for Treating Polyglutamine Aggregation-Caused Disease or Suppressing Onset Thereof |
| 07/01/2010 | US20100167993 Compounds for Enhancing p21 Expression and Methods of Use Thereof |
| 07/01/2010 | US20100167983 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| 07/01/2010 | US20100166893 Herbal composition for reducing add/adhd and method thereof |
| 07/01/2010 | US20100166889 Method of treating depressive disorders |
| 07/01/2010 | US20100166887 DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS |
| 07/01/2010 | US20100166874 Technology for Preparation of Macromolecular Microspheres |
| 07/01/2010 | US20100166862 Local Complement Inhibition for Treatment of Complement-Mediated Disorders |
| 07/01/2010 | US20100166859 Novel nutraceutical compositions and use thereof |
| 07/01/2010 | US20100166849 Glutathione based delivery system |
| 07/01/2010 | US20100166846 Management of myoclonus with oral liposomal reduced glutathione |
| 07/01/2010 | US20100166839 Non peptidic renin inhibitors nitroderivatives |
| 07/01/2010 | US20100166836 Transdermal Therapeutic System for Volatile and/or Thermo-Labile Substances |
| 07/01/2010 | US20100166762 Method of treating a pathological syndrome |
| 07/01/2010 | US20100166759 Metallothionein-Derived Peptide Fragments |
| 07/01/2010 | US20100166735 Methods and compositions for reduction of side effects of therapeutic treatments |
| 07/01/2010 | US20100166728 Novel Highly Functional Enzyme Having Modified Substrate-Specificity |
| 07/01/2010 | US20100166712 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors |
| 07/01/2010 | US20100166710 Compositions and Methods for Inducing Neuronal Differentiation |
| 07/01/2010 | US20100166703 Use of il-6/il-6 chimera in huntington's disease |
| 07/01/2010 | US20100166674 Transdermal delivery rate control using amorphous pharmaceutical compositions |
| 07/01/2010 | US20100166670 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity |
| 07/01/2010 | US20100166655 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 07/01/2010 | CA2772760A1 Small molecule inhibitors of necroptosis |
| 07/01/2010 | CA2748397A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use |
| 07/01/2010 | CA2748294A1 Piperidine derivatives useful as orexin antagonists |
| 07/01/2010 | CA2748251A1 Novel bicyclic heterocyclic compound |
| 07/01/2010 | CA2748235A1 Ethanamine compounds and their use for treating depression |
| 07/01/2010 | CA2748163A1 Agents for treating spinal canal stenosis |
| 07/01/2010 | CA2748124A1 Ppar agonist compositions and methods of use |
| 07/01/2010 | CA2747996A1 Compounds and methods for enhancing erythropoiesis |
| 07/01/2010 | CA2747951A1 Compounds and methods for the treatment of autoimmune and inflammatory disease |
| 07/01/2010 | CA2747811A1 Coumarin-based compounds |
| 07/01/2010 | CA2747805A1 Methods for treating or preventing cancer and neurodegenerative diseases |
| 07/01/2010 | CA2747750A1 Gamma secretase modulators |
| 07/01/2010 | CA2747744A1 Gamma secretase modulators |
| 07/01/2010 | CA2746055A1 Triple reuptake inhibitors and methods of their use |
| 07/01/2010 | CA2744714A1 Amino pyrazole compound |
| 06/30/2010 | EP2202295A1 Method for efficient production of monocyte-derived multipotent cell (momc) |
| 06/30/2010 | EP2202240A1 Compound |
| 06/30/2010 | EP2202233A1 Method for producing pyrazole fused ring derivative |
| 06/30/2010 | EP2202232A1 1,2,4-oxadiazole derivatives and their therapeutic use |
| 06/30/2010 | EP2202227A1 Novel histidine derivative |
| 06/30/2010 | EP2201963A1 Glutamate modulating agents in the treatment of mental disorders |
| 06/30/2010 | EP2201959A2 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases |
| 06/30/2010 | EP2201950A1 Compounds and methods for treating autism spectrum disorders |
| 06/30/2010 | EP2201945A2 Substituted 2-Aminoacetamides and the Use Thereof |
| 06/30/2010 | EP2201944A2 Substituted 2-Aminoacetamides and the Use Thereof |
| 06/30/2010 | EP2201943A1 Novel use of a peptide class of compounds for treating diabetic neuropathic pain |
| 06/30/2010 | EP2201117A2 Extracellular targets for alzheimer's disease |
| 06/30/2010 | EP2201034A1 Neuroprotection using nap-like and sal-like peptide mimetics |
| 06/30/2010 | EP2201011A2 Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same |
| 06/30/2010 | EP2201008A1 Pyridyl sulfonamides as modulators of ion channels |
| 06/30/2010 | EP2201007A1 Cannabinoid receptor ligands |
| 06/30/2010 | EP2201005A1 Novel phenoxazin-3-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/30/2010 | EP2201004A1 Novel benzooxazol- and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/30/2010 | EP2201003A1 Process for the preparation of zolmitriptan, salts and solvates thereof |
| 06/30/2010 | EP2201002A1 5-ht7 receptor antagonists |
| 06/30/2010 | EP2200998A1 Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists |
| 06/30/2010 | EP2200994A1 Condensed compounds with activity at estrogen receptors |
| 06/30/2010 | EP2200989A1 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| 06/30/2010 | EP2200985A1 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| 06/30/2010 | EP2200982A1 Piperidine derivatives as nk3 receptor antagonists |
| 06/30/2010 | EP2200980A1 Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention |
| 06/30/2010 | EP2200968A1 Process for preparing o-desmethylvenlafaxine |
| 06/30/2010 | EP2200649A2 Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| 06/30/2010 | EP2200616A1 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy |
| 06/30/2010 | EP2200615A1 A3 adenosine receptor antagonists |
| 06/30/2010 | EP2200610A2 Co-administration of pimavanserin with other agents |
| 06/30/2010 | EP2200604A1 Methods of increasing sarcosine levels for treating schizophrenia |
| 06/30/2010 | EP2089381B1 Indoles which act as via receptor antagonists |
| 06/30/2010 | EP1943216B1 Prolinamide derivatives as sodium channel modulators |
| 06/30/2010 | EP1891008B1 Oxindoles as kinase inhibitors |
| 06/30/2010 | EP1841757B1 Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| 06/30/2010 | EP1838308B1 [4-(heteroaryl)piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 06/30/2010 | EP1542970B1 Pyrrolidone derivatives as maob inhibitors |
| 06/30/2010 | EP1465616B1 Treatment of statin side effects using uridine derivatives |
| 06/30/2010 | EP1366044B1 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl ]-1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the serotonin reuptake site |
| 06/30/2010 | EP1330436B1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists |
| 06/30/2010 | CN201515889U Pillow for neck |
| 06/30/2010 | CN201515888U A dual purpose pillow for neck portion and waist portion |
| 06/30/2010 | CN1895408B Radix saposhnikoviae Tong Sheng capsules, preparation and quality control method thereof |
| 06/30/2010 | CN1533276B Use of thiazole derivatives for preparing medicine for protecting mitochondria |
| 06/30/2010 | CN101765601A 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof |